A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (FRUITFUL)
Public ClinicalTrials.gov record NCT07011576. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II Study Investigating Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (FRUITFUL)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is an open-label multicenter, single-arm Phase II study of Fruquintinib in combination with FOLFIRI (leucovorin calcium (folinic acid), fluorouracil, and irinotecan) in participants with metastatic colorectal cancer (mCRC). The main goals of this study are to: * Evaluate the efficacy of the combination of fruquintinib + FOLFIRI in the 2nd-line mCRC setting * Evaluate the safety of the combination of fruquintinib + FOLFIRI
Study identification
- NCT ID
- NCT07011576
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 60 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 28, 2025
- Primary completion
- Dec 31, 2026
- Completion
- May 31, 2027
- Last update posted
- Jun 11, 2026
2025 – 2027
United States locations
- U.S. sites
- 14
- U.S. states
- 10
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Rocky Mountain Cancer Center - Primary | Denver | Colorado | 80218 | Recruiting |
| Illinois Cancer Specialists | Arlington Heights | Illinois | 60005 | Recruiting |
| Maryland Oncology Hematology | Columbia | Maryland | 21044 | Recruiting |
| Minnesota Oncology Hematology - Primary | Maple Grove | Minnesota | 55369 | Recruiting |
| Missouri Cancer Associates | Columbia | Missouri | 65201 | Recruiting |
| Oncology Associates of Oregon - Primary | Eugene | Oregon | 97401 | Recruiting |
| Northwest Cancer Specialists - Compass | Portland | Oregon | 97213 | Recruiting |
| Alliance Cancer Specialists | Wynnewood | Pennsylvania | 19096 | Recruiting |
| SCRI Oncology Partners | Nashville | Tennessee | 37203 | Recruiting |
| Texas Oncology - Central/South Texas | Austin | Texas | 78705 | Recruiting |
| Texas Oncology - Gulf Coast | Beaumont | Texas | 77702 | Recruiting |
| Texas Oncology - Northeast Texas | Tyler | Texas | 75702 | Recruiting |
| Virginia Oncology Associates | Norfolk | Virginia | 23502 | Recruiting |
| Blue Ridge Cancer Care (Oncology & Hematology Associates of Southwest VA) | Salem | Virginia | 24153 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07011576, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 11, 2026 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07011576 live on ClinicalTrials.gov.